T2 Biosystems (NASDAQ:TTOO) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of T2 Biosystems (NASDAQ:TTOO – Get Free Report) in a research report issued on Tuesday. The firm set a “sell” rating on the medical equipment provider’s stock.

T2 Biosystems Price Performance

NASDAQ TTOO opened at $0.10 on Tuesday. The stock has a fifty day moving average of $0.13 and a 200-day moving average of $0.63. T2 Biosystems has a 52 week low of $0.05 and a 52 week high of $15.00.

Get T2 Biosystems alerts:

T2 Biosystems (NASDAQ:TTOO – Get Free Report) last announced its quarterly earnings data on Tuesday, May 23rd. The medical equipment provider reported ($1.17) EPS for the quarter. The company had revenue of $2.08 million during the quarter.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp lifted its holdings in T2 Biosystems by 11.4% during the first quarter. State Street Corp now owns 646,500 shares of the medical equipment provider’s stock worth $339,000 after acquiring an additional 66,052 shares in the last quarter. Jane Street Group LLC bought a new position in T2 Biosystems during the third quarter worth about $28,000. Virtu Financial LLC lifted its holdings in shares of T2 Biosystems by 1,763.1% in the second quarter. Virtu Financial LLC now owns 323,427 shares of the medical equipment provider’s stock valued at $52,000 after purchasing an additional 306,067 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of T2 Biosystems by 449.5% in the third quarter. Bank of New York Mellon Corp now owns 538,540 shares of the medical equipment provider’s stock valued at $61,000 after purchasing an additional 440,531 shares in the last quarter. Finally, Anson Funds Management LP bought a new stake in shares of T2 Biosystems in the first quarter valued at about $242,000. 27.55% of the stock is currently owned by institutional investors.

About T2 Biosystems

(Get Free Report)

T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.

Featured Articles

• Five stocks we like better than T2 Biosystems
• Is It Time To Take Another Bite Of Chewy, Inc? 
• GreenPower Motor Company Shifts Into High Gear 
• Is the Microsoft Deal Driving Applied Optoelectronics 300% Gain?
• Can Unity Software Sustain The Momentum?
• Nvidia Invested $50 million into This AI Drug Discovery Biotech

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.